Global DDF Summit – Drug Delivery & Formulation
May 18-20, 2026
Berlin, Germany
https://ddfevent.com/live/en/page/home
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Downloads
Upcoming
Events
BIO International Convention
June 22-25, 2026
San Diego, USA
https://convention.bio.org/
CRS (Controlled Release Society) Annual Meeting
July 6-9, 2026
Lisbon, Portugal
https://www.controlledreleasesociety.org/events/crs-2026-annual-meeting-exposition
CPHI South East Asia
July 8-10, 2026
Bangkok, Thailand
https://www.cphi.com/sea/en/attend/attend/why-attend.html
CPHI Milan
October 6-8, 2026
Milan, Italy
https://www.cphi.com/europe/en/exhibit/book-your-stand-milan.html
PODD – Partnership Opportunities in Drug Delivery
October 29-30, 2026
Boston, USA
https://poddconference.com/
BIO-Europe
November 9-11, 2026
Cologne, Germany
https://informaconnect.com/bioeurope/
Past
Events
Archive
AT Uro Congress
May 22-24, 2025
Vienna, Austria
International Partnering in Life-Sciences Society (IPLS)
September 29 – October 1, 2025
Berlin, Germany
https://ipls.online/events/
CPHI Frankfurt
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
PharmaSynergyRx
February 5-6, 2026
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2026/
EuroPLX
March 2-3, 2026
Lisbon, Portugal
https://www.raucon.com/euro-plx/euro-p-l-x-90
BIO-Europe Spring
March 23-25, 2026
Lisbon, Portugal
https://informaconnect.com/bioeurope-spring/
DCAT Week
March 23-26, 2026
New York City, USA
https://dcatweek.org/
PBP World Meeting
March 23-26, 2026
Prague, Czech Republic
https://worldmeeting.org/
analytica
March 24-27, 2026
Munich, Germany
https://analytica.de/de/muenchen/
ARVO Annual Meeting
May 3-7, 2026
Denver, USA
https://www.arvo.org/annual-meeting
Latest
News
Specialty pharmaceutical company AMW takes big steps
Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialist pharmaceutical company with bright prospects. The company develops and distributes transdermal systems, i.e. active ingredients that enter the body through the skin, as well as implants loaded with highly effective active ingredients, which release their active ingredient evenly to the body for months and dissolve completely. AMW is supported by well-known investors. In a recent financing round to finance growth, investors reaffirmed their commitment to AMW and contributed a further six million euros.
read moreChamber of Commerce Munich and Upper Bavaria: Training company 2016
This company ensures qualitythrough vocational training in several occupations.
read moreFor the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.
The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.
read moreBfArM approvals from DCP procedure for Rivastigmin patches granted for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic
On 28 August 2015, the BfArM granted approvals from DCP procedures for rivastigmin patches at doses 4.6 mg/24 h and 9.5 mg/24 h for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic.
read moreSuccessful financing round for pharmaceutical company AMW
AMW GmbH (Arzneimittelwerk Warngau) has received follow-on financing to advance the development and commercialization process for its drug delivery systems. Together with BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM-Fonds and IBG Beteiligungsgesellschaft, the existing investors are putting in a total of up to seven million euros. The funds will be used for the marketing of the existing product portfolio and the development of a new technology for the controlled release of pharmaceuticals. AMW GmbH produces active ingredient implants as well as transdermal systems in the fast-growing fields of oncology, pain therapy and neurology.
read more